Supported by double-digit income growth in key business segments, Royal Bank of Canada (RY) Wednesday reported stronger than expected fourth-quarter profit, which is 17% higher compared to last year.
On a per-share basis, earnings of the financial services company advanced 17% to C$2.20 during the quarter, exceeding analysts’ forecast. Net income was C$3.25 billion, up 15% compared to last year. Driving the bottom-line growth, income from the retail banking segment rose 10% aided by strong margin growth, higher deposits and an increase in residential and commercial lending.
Wealth management and capital markets segments recorded 13% and 14% growth respectively. The insurance division’s profit climbed 20%, while investor treasury services remained broadly flat. The overall performance benefitted from the back-to-back interest rate hikes over the last year and the resultant improvement in deposit spreads.
Driving the bottom-line growth, income from the retail banking segment rose 10% higher deposits and an increase in residential and commercial lending
Net revenues moved up 1.2% to C$10.67 billion in the fourth quarter. There was an 8% growth in net interest income to C$4.73 billion. The bank’s common equity tier-1 ratio, a measure of its overall performance, was 11.5% at the end of October, up 60 basis points compared to last year. Return on common equity increased by 100 basis points to 17.6%.
“Looking ahead, we remain focused on investing in our people and technology, and offering more personalized insights and connectivity to deliver more value for both our clients and shareholders,” said RBC CEO Dave McKay.
Canadian banks have been witnessing a marked improvement in margin growth in recent times, owing mainly to the higher interest rates. The central bank raised the benchmark interest rate as many as five times in the past twelve months.
Royal Bank of Canada shares closed the last trading session higher. The stock lost about 15% since the beginning of the year.
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
